Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency
Salvatore Monti, B. Fazzalari, Valerio Renzelli, Claudia Bongermino et autres
Background: Lenvatinib, a multi-kinase inhibitor widely used in the treatment of radioiodine-refractory differentiated thyroid carcinoma (RR-DTC), has shown remarkable efficacy and improvement in progression-free survival (PFS), although its use is associated with a variety of side effects. Among them, adrenal insufficiency (AI) …
it (code pays fourni par la source)